{"entity":{"id":"paper-chen-prophet-nsclc-cancer-cell-2023","kind":"paper","name":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","aka":[],"tldr":"A personalised blood test tracking 50 of each patient's tumour mutations found leftover lung cancer after surgery months before scans did.","summary":"PROPHET deep-sequences 50 patient-specific variants to detect residual disease, with a limit of detection of 0.004 per cent. Applied with fixed-panel assays to 760 plasma samples from 181 prospectively enrolled patients with early-stage non-small cell lung cancer, it had higher sensitivity at baseline (45 per cent), outperformed fixed panels for prognosis and gave a median lead time of 299 days to radiologically confirmed recurrence. Non-canonical personalised variants made up 98.2 per cent of those tracked, with prognostic effects similar to canonical ones, and a proposed tumour-node-metastasis-blood classification outperformed TNM staging at the adjuvant decision point.","asOf":"2026-11-04","links":[{"label":"Chen et al., Cancer Cell 2023","url":"https://doi.org/10.1016/j.ccell.2023.08.010"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37683638/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["diagnostics"],"technologies":["mrd-testing"],"targets":[],"drugs":["brprophet"],"companies":["burning-rock"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"journal":"Cancer Cell","year":2023,"doi":"10.1016/j.ccell.2023.08.010","pmid":"37683638","authors":"Chen K, Yang F, Shen H, et al.","paperType":"translational","findings":["Limit of detection 0.004%.","Baseline sensitivity 45%.","Median lead time 299 days to radiological recurrence."],"whatItMeans":"Personalised panels outperform fixed gene panels after lung cancer surgery, at limits in the tens of parts per million.","caveats":["Company co-authored.","No clone attribution."],"participants":181},"route":"/key-papers/paper-chen-prophet-nsclc-cancer-cell-2023/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"brprophet","kind":"drug","name":"brPROPHET","route":"/drugs/brprophet/"}],"company":[{"id":"burning-rock","kind":"company","name":"Burning Rock Biotech","route":"/companies/burning-rock/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"journal":[{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/"}]}}